BVS
Bioventus Inc
13.50$
-0.6%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Balance Sheet
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +13.2% | – | – | – | +6.7% | +4.7% | +147.9% | +12.0% | -40.9% | -10.2% | -6.1% | |
| – | – | +4.4% | – | – | – | +23.4% | +15.7% | +24.2% | +3.6% | -1.7% | +2.8% | -1.0% | |
| – | – | -68.6% | – | – | – | +50.8% | +34.6% | -49.4% | -31.3% | +22.5% | +12.5% | +23.2% | |
| – | – | -68.6% | – | – | – | +50.8% | +34.6% | -49.4% | -31.3% | +22.5% | +12.5% | +23.2% | |
| – | – | +15.8% | – | – | – | +16.5% | +3.7% | +41.5% | +9.1% | -9.9% | +3.7% | +0.7% | |
| – | – | +31.9% | – | – | – | -0.3% | +6.6% | +111.8% | +37.4% | +7.7% | +1.3% | -11.1% | |
| – | – | – | – | – | – | +315.1% | +10.5% | +5.2% | – | – | – | – | |
| – | – | +17.5% | – | – | – | +0.0% | +0.0% | +196.4% | -94.9% | +0.0% | +0.0% | +0.0% | |
| – | – | +16.3% | – | – | – | -8.7% | -11.5% | +262.7% | -8.0% | -24.6% | -16.1% | -9.0% | |
| – | – | +16.6% | – | – | – | +9.9% | +7.2% | +97.6% | +38.8% | -38.6% | -8.0% | -16.1% | |
| – | – | +68.1% | – | – | – | +36.1% | +37.7% | +47.5% | +68.1% | -42.3% | +19.9% | -23.8% | |
| – | – | +378.5% | – | – | – | +90.5% | +50.0% | +20.3% | +83.3% | -15.8% | -1.8% | -29.7% | |
| – | – | +55.5% | – | – | – | -21.5% | -31.3% | +282.5% | +116.9% | -37.2% | +2.8% | -53.9% | |
| – | – | – | – | – | – | -0.9% | -7.8% | +95.9% | +13.4% | -4.7% | -16.0% | -9.5% | |
| – | – | +8.4% | – | – | – | -1.6% | -0.5% | +222.6% | -29.1% | -46.6% | -14.8% | +24.4% | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +0.0% | +0.0% | +2.2% | +0.0% | +0.0% | +0.0% | -33.7% | +20.6% | +35.0% | +2.0% | +4.3% | +5.4% |
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.